Physician profile
Dhruv Lowe
NPI 1255771697
$5,143.67
in general payments reported to CMS, 2019-2025
27 companies · $1,786 in 2025
The $1,786 reported for 2025 was more than what 76% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $32.85 · 2023: $1,012 · 2024: $2,312 · 2025: $1,786.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,044 · Education: $66.38.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,044.44 |
| Education | $66.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,543.52 | 2022-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $576.25 | 2023-2025 | Xifaxan, Trulance |
| Pfizer INC. | $494.81 | 2023-2025 | |
| Janssen Biotech, INC. | $462.38 | 2023-2025 | Stelara, Tremfya, Remicade |
| Genzyme Corporation | $273.66 | 2023-2025 | |
| Qol Medical, LLC | $217.09 | 2024-2025 | Sucraid, Sucraid |
| Ardelyx, INC. | $163.01 | 2023-2025 | Ibsrela |
| Celgene Corporation | $162.33 | 2023-2024 | Zeposia |
| Celltrion USA INC. | $134.89 | 2024-2025 | Vegzelma, Zymfentra |
| E.R. Squibb & Sons, L.L.C. | $126.87 | 2023 | Zeposia |
| Madrigal Pharmaceuticals | $120.97 | 2024-2025 | Rezdiffra, Resmetirom |
| Takeda Pharmaceuticals U.S.A., INC. | $111.49 | 2023-2025 | Entyvio, Eohilia |
| Lilly USA, LLC | $100.76 | 2023-2025 | Omvoh |
| Intercept Pharmaceuticals, INC. | $99.28 | 2024-2025 | |
| Janssen Scientific Affairs, LLC | $75.50 | 2023 | Tremfya, Stelara |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ipsen Biopharmaceuticals, INC | $71.10 | 2025 | Iqirvo |
| Medtronic, INC. | $65.57 | 2025 | Pillcam |
| Phathom Pharmaceuticals, INC. | $61.06 | 2024-2025 | Voquezna |
| Gilead Sciences, INC. | $56.32 | 2024-2025 | |
| Braintree Laboratories, INC. | $54.37 | 2023 | Sutab, Suflave |
| Regeneron Healthcare Solutions, INC. | $50.56 | 2024-2025 | Dupixent |
| Ironwood Pharmaceuticals, INC | $34.16 | 2024 | |
| Amgen INC. | $27.27 | 2023 | Amjevita, Avsola |
| Ferring Pharmaceuticals INC. | $16.95 | 2023 | Rebyota |
| Fresenius Kabi USA, LLC | $15.71 | 2024 | Idacio |
| W. L. Gore & Associates, INC. | $14.39 | 2023 | Gore Cardioform Septal Occluder |
| Evoke Pharma, INC. | $13.40 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dhruv Lowe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.